Evidence map›Paper›PMID 41697112›Full record

SynthesisFuture oncology (London, England)2026

Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis.

Jingqi Jiang, Yuhan Wang, Jiangtao Bai, Gaoyang Yang, Hanzhang Wang, Hui Ding, Yunxin Zhang, Zhenxing Zhai, Zhilong Dong, Zhiping Wang

Abstract readNetwork Meta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingqi JiangDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.ORCID 0000-0001-8907-2489
Yuhan WangDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Jiangtao BaiDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Gaoyang YangDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Hanzhang WangDepartment of Pathology & Laboratory Medicine UConn Health Farmington, CT, USA.
Hui DingDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Yunxin ZhangDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Zhenxing ZhaiDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Zhilong DongDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.
Zhiping WangDepartment of Urology, The Second Hospital of Lanzhou University, Gansu Provincial Key Laboratory of Urological Disease Research, Lanzhou, China.ORCID 0000-0002-8140-591X

Funding

The National Natural Science Foundation of China 81874088
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsProstatic NeoplasmsAndrogen AntagonistsAndrostenesBayes TheoremDocetaxelHumansMaleNeoplasm MetastasisTreatment OutcomeabirateroneAndrogen AntagonistsAndrostenesDocetaxelandrogen receptor inhibitorsdocetaxelmetastatic hormone-sensitive prostate cancernetwork meta-analysistreatment

Identifiers

PMID41697112
PMCPMC12947570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.